Literature DB >> 33001270

The botanical component p-hydroxycinnamic acid suppresses the growth and bone metastatic activity of human prostate cancer PC-3 cells in vitro.

Masayoshi Yamaguchi1, Tomiyasu Murata2, Joe W Ramos3.   

Abstract

Bone metastatic prostate cancer is one of the most common malignancies in developed countries and the second leading cause of cancer-related death in men. There remains no effective treatment for metastatic prostate cancer. We investigate here the anticancer effects of botanical component p-hydroxycinnamic acid (HCA) on the PC-3 cells in vitro model of bone metastatic human prostate cancer. Culturing with HCA (10-1000 nM) suppressed colony formation and growth of PC-3 cells. Mechanistically, culturing with HCA decreased protein levels of Ras, PI3K, Akt, MAPK, NF-κB p65 and β-catenin related to processes of cell signaling and transcription, and it increased levels of p21, p53, retinoblastoma and regucalcin, which are suppressors in carcinogenesis. These alterations can lead to suppression of cell growth. Furthermore, culturing with HCA increased cell death and caspase-3 levels. The effects of HCA on the growth and death of PC-3 cells were blocked by culturing with CH223191, an antagonist of aryl hydrocarbon receptor (AHR), suggesting that HCA effects are partly involved in AHR signaling. Interestingly, HCA suppressed the stimulatory effects of Bay K 8644, an agonist of L-type calcium channel, on the growth of PC-3 cells. Coculturing of PC-3 cells and preosteoblastic MC-3T3 E1 cells increased osteoblastic mineralization. This increase was not attenuated by treatment of HCA that stimulated mineralization. Notably, osteoclastogenesis from preosteoclastic RAW264.7 cells was enhanced by coculturing with PC-3 cells, and this enhancement was suppressed by treatment with HCA (10-1000 nM). Thus, HCA has anticancer effects on bone metastatic human prostate cancer, potentially providing a novel therapeutic tool.

Entities:  

Keywords:  Aryl hydrocarbon receptor; Bay K 8644; Bone metastasis; Cell death; Cell proliferation; PC-3 cells; Prostate cancer; p-hydroxycinnamic acid

Mesh:

Substances:

Year:  2020        PMID: 33001270     DOI: 10.1007/s00432-020-03405-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  34 in total

1.  Phytocomponent p-hydroxycinnamic acid inhibits osteoclast-like cell formation in mouse bone marrow cultures.

Authors:  Ying Ling Lai; Masayoshi Yamaguchi
Journal:  Int J Mol Med       Date:  2007-01       Impact factor: 4.101

2.  Phytocomponent p-hydroxycinnamic acid stimulates bone formation and inhibits bone resorption in rat femoral tissues in vitro.

Authors:  Ying Ling Lai; Masayoshi Yamaguchi
Journal:  Mol Cell Biochem       Date:  2006-10-12       Impact factor: 3.396

3.  The antiproliferative effect of dietary fiber phenolic compounds ferulic acid and p-coumaric acid on the cell cycle of Caco-2 cells.

Authors:  Birgit Janicke; Cecilia Hegardt; Morten Krogh; Gunilla Onning; Björn Akesson; Helena M Cirenajwis; Stina M Oredsson
Journal:  Nutr Cancer       Date:  2011       Impact factor: 2.900

4.  Events associated with apoptotic effect of p-Coumaric acid in HCT-15 colon cancer cells.

Authors:  Saravana Kumar Jaganathan; Eko Supriyanto; Mahitosh Mandal
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

5.  Overexpression of regucalcin suppresses cell death in cloned rat hepatoma H4-II-E cells induced by tumor necrosis factor-alpha or thapsigargin.

Authors:  Takako Izumi; Masayoshi Yamaguchi
Journal:  J Cell Biochem       Date:  2004-05-15       Impact factor: 4.429

6.  Oral administration of phytocomponent p-hydroxycinnamic acid has a preventive effect on bone loss in streptozotocin-induced diabetic rats.

Authors:  Masayoshi Yamaguchi; Satoshi Uchiyama; Ying Ling Lai
Journal:  Int J Mol Med       Date:  2007-05       Impact factor: 4.101

7.  Effect of BayK 8644 on [Ca²⁺]i and viability in PC3 human prostate cancer cells.

Authors:  Zhen-Rung Lai; Chiang-Ting Chou; Shiuh-Inn Liu; Wei-Zhe Liang; Jong-Khing Huang; Chung-Ren Jan
Journal:  Chin J Physiol       Date:  2013-12-31       Impact factor: 1.764

Review 8.  Systemic treatment for metastatic prostate cancer.

Authors:  Gwenaelle Gravis
Journal:  Asian J Urol       Date:  2019-02-11

Review 9.  Overview of RAW264.7 for osteoclastogensis study: Phenotype and stimuli.

Authors:  Lingbo Kong; Wanli Smith; Dingjun Hao
Journal:  J Cell Mol Med       Date:  2019-03-20       Impact factor: 5.310

Review 10.  Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.

Authors:  Marlena Janiczek; Łukasz Szylberg; Anna Kasperska; Adam Kowalewski; Martyna Parol; Paulina Antosik; Barbara Radecka; Andrzej Marszałek
Journal:  J Immunol Res       Date:  2017-10-03       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.